2016
DOI: 10.1002/jlcr.3409
|View full text |Cite
|
Sign up to set email alerts
|

Synthesis of [3H] and [2H6]AZD6642, an inhibitor of 5‐lipoxygenase activating protein (FLAP)

Abstract: An AstraZeneca effort to identify a 5-lipoxygenase activating protein inhibitor with good drug-like properties resulted in the identification of AZD6642. To further understand its drug metabolism and pharmacokinetic properties, it was required labeled with tritium. The tritiation of AZD6642 was effected by Ir-catalyzed exchange chemistry to give an average of one tritium per molecule. Additionally, a stable isotope labeled version of AZD6642 was required to support bioanalytical studies. The synthesis originat… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2017
2017
2022
2022

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(1 citation statement)
references
References 19 publications
(22 reference statements)
0
1
0
Order By: Relevance
“…Consequently, the tritiated analogues were prepared using a specific iridium phosphine carbene catalyst in the presence of tritium to further understand drug metabolism and pharmacokinetic properties (Scheme 153). 402 Dopamine receptors, especially those in the D2 family, play a significant role in a variety of disorders involving the central nervous system including Parkinson's disease (PD), restless leg syndrome (RLS), Huntington's chorea, multiple system atrophy (MSA), and so on. As an example, for small molecules which bind with high affinity to these receptors, Subburaju and coworkers developed tritium incorporated MCL-536 which helps to quantify D2 high sites in schizophrenia and PD patients in vivo (Scheme 154).…”
Section: Drug Developmentmentioning
confidence: 99%
“…Consequently, the tritiated analogues were prepared using a specific iridium phosphine carbene catalyst in the presence of tritium to further understand drug metabolism and pharmacokinetic properties (Scheme 153). 402 Dopamine receptors, especially those in the D2 family, play a significant role in a variety of disorders involving the central nervous system including Parkinson's disease (PD), restless leg syndrome (RLS), Huntington's chorea, multiple system atrophy (MSA), and so on. As an example, for small molecules which bind with high affinity to these receptors, Subburaju and coworkers developed tritium incorporated MCL-536 which helps to quantify D2 high sites in schizophrenia and PD patients in vivo (Scheme 154).…”
Section: Drug Developmentmentioning
confidence: 99%